Biosafety of in vivo adenovirus-p53 intravesical administration in mice

Paul Perrotte, Mark Wood, Joel W. Slaton, Deborah R. Wilson, Lance Pagliaro, Roger E. Price, Colin P.N. Dinney

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


Objectives. To evaluate the biosafety and in vivo biodistribution of intravesical instillation of an adenovirus that contains human p53 gene. Mutations of p53, which are found in as many as 40% of transitional cell carcinomas, are associated with a poor prognosis and resistance to chemotherapy and radiation therapy. Restoration of wild-type p53 status by means of adenoviral-mediated therapy may enhance apoptosis and improve the response to therapy, but the issues of biosafety and toxicity have not yet been addressed. Methods. Adenovirus-p53 (1 x 108, 1 x 109, and 5 x 109 pfu/mL) and luciferase reporter gene (5 x 109) were instilled into the bladders of anesthetized female BALB/c mice. The mice were killed on days 1, 3, 6, and 13, and representative samples of the bladder, ureter, kidney, adrenal gland, ovary, liver, heart, and lung were removed for histologic evaluation. Results. No histologic signs of toxicity were found. The hematologic and biochemical profiles of the mice were normal, with the exception of a transient elevation in liver function tests on day 1 in the three treatment groups. Conclusions. Intravesical instillation of adenovirus- p53 was well tolerated; the bladder urothelium appeared to prevent systemic dissemination. The results of these experiments support the safety of intravesical gene transfer by intravesical instillation. (C) 2000 Elsevier Science Inc.

Original languageEnglish (US)
Pages (from-to)155-159
Number of pages5
Issue number1
StatePublished - Jul 2000

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Biosafety of in vivo adenovirus-p53 intravesical administration in mice'. Together they form a unique fingerprint.

Cite this